- Conditions
- Herpes Zoster, Shingles
- Interventions
- Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
- Biological
- Lead sponsor
- Curevo Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,516 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 14
- States / cities
- Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced May 21, 2026, 4:50 PM EDT